[Risk of post-thrombotic syndrome following direct oral anticoagulant intake: a systematic review and meta-analysis].

Kirill V Lobastov Ilya Schastlivtsev A B Bargandzhiya

Published in: Khirurgiia (2022)

Moderate quality evidence suggests that DOACs are associated with significant less risk of any PTS and severe PTS compared to VKA in patients with deep vein thrombosis. Among all DOACs, only rivaroxaban has clear data confirming PTS risk reduction. The use of flavonoids in adjunction to rivaroxaban can further improve treatment outcomes.

Keyphrases

venous thromboembolism
direct oral anticoagulants
atrial fibrillation
pulmonary embolism
electronic health record
high intensity
case report
quality improvement
body mass index
physical activity
weight loss
artificial intelligence